fr en

Réactifs et instruments pour l'immunologie, la biologie cellulaire et la biologie moléculaire.

D-Thyroxine [51-49-0]

Imprimer

Référence NB-64-10934-50mg

Conditionnement : 50mg

Contactez votre distributeur local :

Téléphone : +1 850 650 7790

Marque : Neo Biotech

Demander plus d'informations

Contactez votre distributeur local :

Téléphone : +1 850 650 7790

Remove All

D-Thyroxine

(Synonyms: Dextroxin, Dextrothyroxine;Biotirmone, Dextrothyroxine, Dextroid, Detyroxin, Dethyrona, Debetrol, Biotirmone) Copy Product Info

Synonyms: Dextroxin, Dextrothyroxine;Biotirmone, Dextrothyroxine, Dextroid, Detyroxin, Dethyrona, Debetrol, Biotirmone

Catalog No. T21383 Copy Product Info

Purity: 97.03%

D-Thyroxine (Dextroxin) could lower cholesterol and also increases hepatic lipase which in turn improves utilization of triglycerides, leading to improve apolipoprotein E cholesterol particles.

Cas No. 51-49-0

For research use only—not for human use. No sales to individuals. Use as intended only.

Select Batch

Purity:97.03%

Appearance:Solid

Color:White

Product Introduction

D-Thyroxine AI Summary

D-Thyroxine exhibits a diverse range of biological activities, making it a potent candidate for multiple therapeutic applications. It inhibits the rat liver nuclear L-triiodothyronine receptor with an IC50 of 35.0 nM and the rat plasma membrane L-triiodothyronine receptor with an IC50 of 2500.0 nM in vitro. Additionally, it displaces [3H]L-689560 from the NMDA receptor glycine site in rat brain membranes with an IC50 of 330.0 nM. D-Thyroxine also inhibits transthyretin amyloidosis by preventing fibril formation and demonstrates moderate activity in stabilizing urea-induced transthyretin dissociation. It exerts various bioactivities, including modulation of Lamin A splicing (potency of 89.1 nM), inhibition of HSD17B4 (IC50 of 12589.3 nM), interaction inhibition between thyroid hormone receptor and steroid receptor coregulator 2 (potency of 5.6 nM), and competition for the Menin-MLL interaction in MLL related leukemias (potency of 12589.3 nM). The compound also inhibits Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia (IC50 of 19905.4 nM), HADH2 (potency of 15848.9 nM), and affects enzymes such as Cytochrome P450 2C9 (IC50 of 6309.6 nM) and Cytochrome P450 1A2 (potency of 15848.93 nM). It blocks the interaction between CBF-beta and RUNX1 for treating Acute Myeloid Leukemia (potency of 11220.2 nM) and inhibits Marburg Virus entry into cells (potency of 22296.9 nM). D-Thyroxine also inhibits the uptake of 3,3',5-triiodothyronine and thyroxine in Xenopus laevis oocytes, with inhibition activities of 21.0% and 76.0%, respectively. It also inhibits the uptake of L-T4 in Oatp14-expressing HEK293 cells with a Ki value of 270.0 nM. In terms of toxicity, it exhibits moderate liver toxicity with hepatotoxicity observed in 40.2% of cases based on clinical trial data, but no acute liver toxicity or other severe liver conditions such as cytolytic hepatitis, cirrhosis, or liver tumors were noted. The compound shows binding affinity and activity in various in vitro assays targeting a wide array of receptors and enzymes. These include a range of receptors such as HRH2, DRD1, ADRB1, ADRB2, ADRB3, OPRK1, CHRNA4, HTR2C, ADRA1A, SLC6A3, HRH1, HTR1A, HTR2A, and CNR1. It functions as both an agonist and antagonist at receptors like DRD1, CHRM2, HTR1A, ADRA1A, ADRA2A, HTR2A, HTR2B, and CNR1 in in vitro cell-based assays, and it inhibits certain enzymes including PDE4D and MAOA. This broad spectrum of interactions suggests significant pharmaceutical potential that could be explored further..

Note: Summary generated by AI. Data source: ChEMBL

Bioactivity

Description	D-Thyroxine (Dextroxin) could lower cholesterol and also increases hepatic lipase which in turn improves utilization of triglycerides, leading to improve apolipoprotein E cholesterol particles.
Synonyms	Dextroxin, Dextrothyroxine;Biotirmone, Dextrothyroxine, Dextroid, Detyroxin, Dethyrona, Debetrol, Biotirmone

Chemical Properties

Molecular Weight	776.87
Formula	C₁₅H₁₁I₄NO₄
Cas No.	51-49-0
Smiles	O(C1=CC(I)=C(O)C(I)=C1)C2=C(I)C=C(C[C@H](C(O)=O)N)C=C2I
Relative Density.	2.4440 g/cm3 (Estimated)

Storage & Solubility Information

Storage

Keep away from direct sunlight,Store at low temperature,Store under nitrogen Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

H2O: < 1 mg/mL (insoluble)

DMSO: 55 mg/mL (70.8 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (2.57 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	1.2872 mL	6.4361 mL	12.8722 mL	64.3608 mL
5 mM	0.2574 mL	1.2872 mL	2.5744 mL	12.8722 mL
10 mM	0.1287 mL	0.6436 mL	1.2872 mL	6.4361 mL
20 mM	0.0644 mL	0.3218 mL	0.6436 mL	3.2180 mL
50 mM	0.0257 mL	0.1287 mL	0.2574 mL	1.2872 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 µL Tween 80 and mix well until fully clarified.

3) Add 450 µL Saline,PBS or ddH₂O and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

Keywords

TSHInhibitorinhibithypercholesterolemiaEndogenous MetaboliteD-ThyroxineDThyroxineD-T4D Thyroxine

Related Tags: D-Thyroxine chemical structure | D-Thyroxine formula | D-Thyroxine molecular weight